Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 1/2 1

Status

Completed 44Unknown 19Active not recruiting 6Withdrawn 5Terminated 4Recruiting 2Not yet recruiting 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 115Gastrointestinal 67Head & Neck 57Gynecologic 36Genitourinary 23Other solid neoplasm 15Sarcoma 12Breast 12Tumor-Agnostic 7CNS 6Plasma cell 4Lymphoid 4Dermatologic 4Other 3Myeloid 1Endocrine 1

Conditions

Recurrence 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma 2Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, B-Cell 1Hodgkin Disease 1Burkitt Lymphoma 1

Interventions

Rituximab 227Cyclophosphamide 142fludarabine 69Vincristine 66Methotrexate 62Doxorubicin 54fludarabine phosphate 53Lenalidomide 49Etoposide 49Cytarabine 48Prednisone 47Dexamethasone 44Filgrastim 43Bortezomib 38Whole-Body Irradiation 34Gemcitabine 34Melphalan 32Radiotherapy 30ibrutinib 29Granulocyte Colony-Stimulating Factor 29Alemtuzumab 29obinutuzumab 28Tacrolimus 28Mycophenolic Acid 28Antilymphocyte Serum 28venetoclax 27Calcium Dobesilate 27Busulfan 27Bendamustine Hydrochloride 27idelalisib 23

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Terminated × Cisplatin × Lymphoid × Clear all
NCT05498220 2026-04-16

Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma

UNC Lineberger Comprehensive Cancer Center

Phase 2 Terminated
5 enrolled 13 charts
Lymphoid

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT02983097 2018-01-19

R²-DHAP

Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH

Phase 1/2 Terminated
34 enrolled
Lymphoid

Burkitt Lymphoma, Lymphoma, Recurrence, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT00920153 2016-09-16

Three Different Therapy Regimens in Treating Patients With Previously Untreated Hodgkin Lymphoma

French Innovative Leukemia Organisation

Phase 3 Terminated
442 enrolled
Lymphoid

Hodgkin Disease, Lymphoma

NCT00367497 2007-11-20

Safety and Efficacy Study of Salvage Chemotherapy (R-ESHAP) to Treat Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma

Keio University

Phase 2 Terminated
5 enrolled
Lymphoid

Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon âš¡